• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance 0

Merck Rises, Bristol-Myers Slides Following Cancer Meeting

By Kurt Osterberg · On April 16, 2018

Shares of Merck (MRK) are rising this morning, while peer Bristol-Myers (BMY) is sliding, after both companies presented new data on their respective cancer immunotherapy treatments at the American Association for Cancer Research annual meeting that began over this weekend.

MERCK’S KEYTRUDA: In conjunction with the AACR meeting, Merck announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with pemetrexed, or ALIMTA, and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer. The addition of Keytruda to pemetrexed plus platinum chemotherapy achieved a significant improvement in progression-free survival, or PFS, with a reduction in the risk of progression or death of nearly half for patients in the KEYTRUDA combination arm, compared with chemotherapy alone, Merck stated.

BRISTOL’S OPDIVO: Meanwhile, Bristol-Myers Squibb announced initial results from the pivotal Phase 3 study, CheckMate -227, evaluating the Opdivo 3 mg/kg plus low-dose Yervoy combination in first-line advanced non-small cell lung cancer patients with high tumor mutational burden greater than or equal to10 mutations/megabase. In the Phase 3 CheckMate -227 trial, Opdivo plus low-dose Yervoy reduced the risk of progression or death by 42% versus chemotherapy in first-line lung cancer patients with high tumor mutational burden. The one-year progression-free survival rate was more than triple with the combination versus chemotherapy, or 43% vs. 13%, in first-line non-small cell lung cancer patients with high TMB greater than or equal to10 mut/Mb, the company stated.

PRICE ACTION: In early trading, Merck shares have gained $1.79, or 3%, to $58.97 while Bristol-Myers shares have fallen over 5% to $55.50.
 

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    STEPN Sneaker NFTs Sell For $100, Previously Worth $1200

  • Finance

    NFT Prices in Free Fall – 5 NFT Collections to Start Buying Today

  • Finance

    5 NFTs Trending on Twitter Going Cheap to Invest in Now

No Comments

Leave a reply Cancel reply

Top Finance

  • 3 Best Large-Cap Blend Mutual Funds For Enticing Returns 3 Best Large-Cap Blend Mutual Funds For Enticing Returns
  • What is Value Chain Analysis? How to Deliver Value & Gain a Competitive Advantage What is Value Chain Analysis? How to Deliver Value & Gain a Competitive Advantage
  • Hedge Funds In The US Hedge Funds In The US
  • 5 Ridiculously Useful Non-Monetary Reward Examples that Improve Employee Engagement 5 Ridiculously Useful Non-Monetary Reward Examples that Improve Employee Engagement
  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce

New Posts

  • STEPN Sneaker NFTs Sell For $100, Previously Worth $1200

    STEPN Sneaker NFTs Sell For $100, Previously Worth $1200

    June 20, 2022
  • NFT Prices in Free Fall – 5 NFT Collections to Start Buying Today

    NFT Prices in Free Fall – 5 NFT Collections to Start Buying Today

    June 20, 2022
  • 5 NFTs Trending on Twitter Going Cheap to Invest in Now

    5 NFTs Trending on Twitter Going Cheap to Invest in Now

    June 20, 2022
  • Bill Gates – ‘NFTs & Crypto Based on Greater Fool Theory’

    Bill Gates – ‘NFTs & Crypto Based on Greater Fool Theory’

    June 20, 2022
  • Actor Seth Green Pays $300,000 to Recover his Stolen BAYC NFT

    Actor Seth Green Pays $300,000 to Recover his Stolen BAYC NFT

    June 20, 2022
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018-2021 NJCEE. All Rights Reserved.